- Home
- SPEG vs MCRB Comparison
SPEG vs MCRB Comparison
Compare SPEG & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPEG | MCRB |
|---|---|---|
| Founded | 2024 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.6M | 139.7M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | SPEG | MCRB |
|---|---|---|
| Price | $10.15 | $8.64 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.33 |
| AVG Volume (30 Days) | 21.5K | ★ 90.0K |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.77 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.95 | $0.36 |
| 52 Week High | $11.03 | $29.98 |
Technical Indicators
Market Signals| Indicator | SPEG | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 69.08 | 35.06 |
| Support Level | $10.11 | $7.85 |
| Resistance Level | $10.35 | $9.60 |
| Average True Range (ATR) | 0.00 | 0.53 |
| MACD | -0.00 | 0.22 |
| Stochastic Oscillator | 100.00 | 29.50 |
Price Performance
Historical ComparisonAbout SPEG Silver Pegasus Acquisition Corp Class A Ordinary Shares
Silver Pegasus Acquisition Corp is a blank check company.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.